Chikungunya Vaccine Phase 3 Trial Advances After Promising Midstage Results
Themis Bioscience is moving toward a chikungunya vaccine phase 3 trial after its candidate, MV-CHIK, achieved its primary goal in Phase 2 testing. The vaccine, built on a measles vector platform licensed from Institut Pasteur, induced neutralizing antibodies against chikungunya across all study groups, with seroconversion rates ranging from 86% to 100%. According to the Mayo Clinic, chikungunya causes severe joint pain and fever and has no approved treatment or vaccine, making this development especially significant for public health.
What Is Chikungunya and Why a Vaccine Is Urgently Needed
Chikungunya has been identified in dozens of countries, primarily in Africa, and is transmitted by the same mosquitoes that carry Zika and dengue. The disease causes debilitating joint pain severe enough to cause victims to stoop, which is the origin of its name from the Kimakonde language meaning to become contorted. Because it shares symptoms with Zika and dengue, it is frequently misdiagnosed, complicating outbreak response.
There are currently no approved treatments or vaccines for chikungunya anywhere in the world. The FDA recently added the disease to its list of conditions eligible for a priority review voucher upon marketing approval, a designation that Themis CEO Erich Tauber described as a clear indication that development of a vaccine is urgently needed.
How the MV-CHIK Chikungunya Vaccine Phase 3 Trial Candidate Was Tested
The Phase 2 study enrolled 263 healthy participants and tested MV-CHIK at two dose levels. To assess whether prior measles vaccination would affect immunogenicity, two groups received Priorix, a live attenuated measles, mumps, and rubella vaccine from GlaxoSmithKline, before receiving MV-CHIK. The remaining groups received MV-CHIK without prior measles vaccination.
All participants received two injections of the candidate vaccine. Themis reported that MV-CHIK induced neutralizing antibodies against chikungunya in all groups after the two dose regimen.
3 Alarming Findings From the Phase 2 Chikungunya Vaccine Trial
1. Seroconversion Rates Reached 86% to 100% Across All Groups
The chikungunya vaccine phase 3 trial candidate achieved seroconversion rates ranging from 86% to 100% across all study groups after two injections. Seroconversion confirms that the immune system has responded to the vaccine by producing neutralizing antibodies capable of fighting the virus. This result was consistent across all dose levels and vaccination histories tested.
2. Prior Measles Vaccination Did Not Reduce Vaccine Effectiveness
A key concern for any vaccine built on a measles vector platform is whether pre-existing immunity to measles, which is widespread globally due to childhood vaccination programs, might blunt the immune response to the chikungunya component. The Phase 2 study found that prior measles vaccination did not affect immunogenicity, a critical finding that strengthens the case for the chikungunya vaccine phase 3 trial by confirming the platform works across populations regardless of measles vaccination history.
3. The FDA Has Designated Chikungunya for Priority Review Voucher Eligibility
The FDA’s decision to add chikungunya to its priority review voucher program signals regulatory recognition that an approved vaccine is urgently needed. This designation provides an additional commercial incentive for developers pursuing chikungunya vaccine phase 3 trial completion, potentially accelerating both development timelines and market entry for the first approved vaccine against the disease.
The Competitive Landscape for Chikungunya Vaccine Development
Themis is not alone in pursuing a chikungunya vaccine phase 3 trial. PaxVax has received FDA Fast Track Designation for its own Phase 2 chikungunya candidate. Bharat Biotech and Moderna also have candidates in early human testing. The concentration of development activity across multiple companies reflects both the unmet need and the growing recognition of chikungunya as a priority infectious disease target.
FOMAT conducts Phase I through Phase IV clinical research across a national network of investigator sites throughout the United States. To learn more about active infectious disease and vaccine studies, visit our patient active studies page.